Christopher J. Centeno

Christopher J. Centeno

Auto-generated profile, based on publicly available information

Christopher J. Centeno

The Centeno-Schultz Clinic, Broomfield, Colorado, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2008
Verified
Journal Article
Closed access
CCChristopher J Centeno
Christopher J Centeno
DBDan Busse
Dan Busse
JKJohn Kisiday
John Kisiday
CKCristin Keohan
Cristin Keohan
Michael FreemanMichael Freeman
Michael Freeman
DKDavid Karli
David Karli

1 December 2011 in Current Stem Cell Research & Therapy
Verified
Journal Article
Closed access
PDF file
CCChristopher J. Centeno
Christopher J. Centeno
JSJohn R. Schultz
John R. Schultz
MCMichelle Cheever
Michelle Cheever
Michael FreemanMichael Freeman
Michael Freeman
SFStephen Faulkner
Stephen Faulkner
RHRonald Hanson
Ronald Hanson
Mesenchymal stem cells (MSCs) hold great promise as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of MSCs, showing their capabilities for differentiating into orthopedic tissues such as muscle, bone, cartilage, and tendon. However, the safety of culture expanded MSCs for human use has only just begun to be reported. Methods: Between 2006 and 2010, two groups of patients were treated for various orthopedic conditions with cultureexpanded, autologous, bone marrow-derived MSCs (group 1: n=50; group 2: n=290-one patient in both groups). Cells were cultured in monolayer culture flasks using an autologous platelet lysate technique and re-injected into peripheral joints or into intervertebral discs with use of c-arm fluoroscopy. While both groups had prospective surveillance for complications, Group 1 additionally underwent 3.0T MRI tracking of the re-implant sites. Results: The mean age of patients treated was 53 +/- 13.85 years; 214 were males and 125 females with mean follow-up time from any procedure being 435 days +/- 261 days. Number of contacts initiated based on time from first procedure was 482 at 3 months, 433 at 6 months, 316 contacts at 12 months, 110 contacts at 24 months, and 22 contacts at 36 months. For Group 1, 50 patients underwent 210 MRI surveillance procedures at 3 months, 6 months, 1, 2, and 3 years which failed to demonstrate any tumor formation at the re-implant sites. Formal disease surveillance for adverse events based on HHS criteria documented significantly less morbidity than is commonly reported for more invasive surgical procedures, all of which were either self-limited or were remedied with therapeutic measures. Two patients were diagnosed with cancer out of 339 patients treated since study inception; however, this was almost certainly unrelated to the MSC therapy and the neoplasm rate in similar to that seen in the U.S. Caucasian population. Knee outcome data was collected on a subset of patients. Here, > 75% improvement was reported in 41.4% while decreasing the improvement threshold to > 50% improvement, 63.2% reported an improvement. At an average reporting time of 11.3 months from first procedure average reported relief in the knee sample equaled 53.1% (n=133 reporting). Conclusions: Using both intensive high field MRI tracking and complications surveillance in 339 patients, no neoplastic complications were detected at any stem cell re-implantation site. These findings are consistent with our prior publication and other published reports that also show no evidence of malignant transformation in vivo, following implantation of MSCs for orthopedic use.

5 September 2011 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
CCChristopher J Centeno
Christopher J Centeno
MFMitchell Fuerst
Mitchell Fuerst
SFStephen J Faulkner
Stephen J Faulkner
Michael FreemanMichael Freeman
Michael Freeman

1 January 2005 in Journal of Whiplash & Related Disorders
Verified
Journal Article
Closed access
PDF file
CCChristopher J. Centeno
Christopher J. Centeno
MFMichael Freeman
Michael Freeman
MIST is an acronym for Minor Impact Soft Tissue. The term arises from the premise that a minimal damage motor vehicle collision cannot result in lasting or significant injury. The literature concerning late whiplash is reviewed, focusing on medical research that supports and refutes the MIST concept. Background. Minor Impact Soft Tissue (MIST) is a descriptive term coined by Allstate Insurance Corporation in 1996 as a means of identifying a segment of patients that are unlikely to sustain chronic symptoms following whiplash and in whom it is presumed that chronic complaints of pain are a psychosocial phenomenon. The MIST concept is based on the assertion that chronic pain following whiplash is not an organic phenomenon. No systematic review of the literature either supporting or refuting the MIST concept has ever been published. Objectives. To review the medical literature for evidence that chronic (late) whiplash is an organic disorder versus a largely psychosocial phenomenon. Methods. The medical literature was reviewed in a narrative format. Results. There are a significant number of studies that support an organic model of late whiplash. Conclusions. Chronic symptoms following whiplash are explained most readily as an organic condition. Absent strong evidence of psychosocial interference with patient recovery, chronic complaints of pain following whiplash should be evaluated and treated as organic illness

1 January 2003 in Journal of Whiplash & Related Disorders
Verified
Journal Article
Closed access
Michael FreemanMichael Freeman
Michael Freeman
CCChristopher J. Centeno
Christopher J. Centeno

1 January 2002 in Journal of Whiplash & Related Disorders
Verified
Journal Article
Closed access
Michael FreemanMichael Freeman
Michael Freeman
CCChristopher J. Centeno
Christopher J. Centeno